Thioridazine elicits potent antitumor effects in colorectal cancer stem cells

Oncology Reports

Volumn 37, Issue 2, 2017, Pages 1168-1174

  Zhang, Chen ^a   Gong, Ping ^a   Liu, Pengfei ^a   Zhou, Ning ^a   Zhou, Yulai ^a   Wang, Yi ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Apoptosis; Cancer stem cells; Colon cancer; Thioridazine

Indexed keywords

CASPASE 3; PROTEIN BAX; PROTEIN BCL 2; THIORIDAZINE; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL INVASION; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; FIBROBLAST CULTURE; FLOW CYTOMETRY; GENE EXPRESSION; HCT 116 CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MITOCHONDRIAL MEMBRANE POTENTIAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CELL MOTION; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; NEOPLASTIC STEM CELLS; THIORIDAZINE;

EID: 85011865411     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.5313     Document Type: Article

References (35)

1. Zhelev Z, Ohba H, Bakalova R, Hadjimitova V, Ishikawa M, Shinohara Y and Baba Y: Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. Cancer Chemother Pharmacol 53: 267-275, 2004.
2. Min KJ, Seo BR, Bae YC, Yoo YH and Kwon TK: Antipsychotic agent thioridazine sensitizes renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen speciesmediated inhibition of Akt signaling and downregulation of Mcl-1 and c-FLIP(L). Cell Death Dis 5: e1063, 2014.
3. Cheng HW, Liang YH, Kuo YL, Chuu CP, Lin CY, Lee MH, Wu AT, Yeh CT, Chen EI, Whang-Peng J, et al: Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data. Cell Death Dis 6: e1753, 2015.
4. Cowap J and Hardy J: Thioridazine in the management of cancerrelated sweating. J Pain Symptom Manage 15: 266, 1998.
5. Zhukovsky DS: Fever and sweats in the patient with advanced cancer. Hematol Oncol Clin North Am 16: 579-588, viii, 2002. viii.
6. Ly KL, Chidgey J, Addington-Hall J and Hotopf M: Depression in palliative care: A systematic review. Part 2. Treatment. Palliat Med 16: 279-284, 2002.
7. Kang S, Dong SM, Kim BR, Park MS, Trink B, Byun HJ and Rho SB: Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis 17: 989-997, 2012.
8. Rho SB, Kim BR and Kang S: A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol 120: 121-127, 2011.
9. Choi AR, Kim JH and Yoon S: Thioridazine specifically sensitizes drug-resistant cancer cells through highly increase in apoptosis and P-gp inhibition. Tumour Biol 35: 9831-9838, 2014.
10. Lu M, Li J, Luo Z, Zhang S, Xue S, Wang K, Shi Y, Zhang C, Chen H and Li Z: Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis. Onco Targets Ther 8: 1543-1552, 2015.
11. Gong L, Wang Y, Tong S, Liu L, Niu L, Yuan Y and Bao Y: Mechanism of killing effect of thioridazine on human lung cancer PC9 cells. Zhongguo Fei Ai Za Zhi 18: 727-733, 2015 (in Chinese).
12. Yin T, He S, Shen G, Ye T, Guo F and Wang Y: Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model. Mol Med Rep 12: 4103-4108, 2015.
13. Meng Q, Sun X, Wang J and Wang Y: Mechanism of thioridazine plus medroxyprogesterone in the treatment of endometrial cancer. Zhonghua Yi Xue Za Zhi 95: 1540-1543, 2015 (in Chinese).
14. Liu JK, Hao YJ, Huang JW, Li X, Cai HB and Peng K: Mechanism of thioridazine-induced apoptosis of human colorectal cancer SW480 cells. Nan Fang Yi Ke Da Xue Xue Bao 35: 511-515, 2015 (in Chinese).
15. Sachlos E, Risueño RM, Laronde S, Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn A, Graham M, et al: Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149: 1284-1297, 2012.
16. Ke XY, Lin Ng VW, Gao SJ, Tong YW, Hedrick JL and Yang YY: Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials 35: 1096-1108, 2014.
17. Dick JE: Looking ahead in cancer stem cell research. Nat Biotechnol 27: 44-46, 2009.
18. Guan Y, Gerhard B and Hogge DE: Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 101: 3142-3149, 2003.
19. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
20. Kim EJ, Kang JI, Kwak JW, Jeon CH, Tung NH, Kim YH, Choi CH, Hyun JW, Koh YS, Yoo ES, et al: The anticancer effect of (1S,2S,3E,7E,11E)-3,7,11, 15-cembratetraen-17,2-olide(LS-1) through the activation of TGF-β signaling in SNU-C5/5-FU, fluorouracil-resistant human colon cancer cells. Mar Drugs 13: 1340-1359, 2015.
21. Zhang C, Tian Y, Song F, Fu C, Han B and Wang Y: Salinomycin inhibits the growth of colorectal carcinoma by targeting tumor stem cells. Oncol Rep 34: 2469-2476, 2015.
22. Amaral L, Kristiansen JE, Abebe LS and Millett W: Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: Potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 38: 1049-1053, 1996.
23. Boeree MJ: Global clinical trials for the treatment of TB with thioridazine. Recent Pat Antiinfect Drug Discov 6: 99-103, 2011.
24. Kleibel F: A method of alleviation of pain in cancer patients. Clinical trial of thioridazine (Melleril and Mellerettes) in 251 patients. Munch Med Wochenschr 103: 2341-2343, 1961 (in German).
25. Smith RC, Baumgartner R, Burd A, Ravichandran GK and Mauldin M: Haloperidol and thioridazine drug levels and clinical response in schizophrenia: Comparison of gas-liquid chromatography and radioreceptor drug level assays. Psychopharmacol Bull 21: 52-58, 1985.
26. Mu J, Xu H, Yang Y, Huang W, Xiao J, Li M, Tan Z, Ding Q, Zhang L, Lu J, et al: Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer. Oncol Rep 31: 2107-2114, 2014.
27. Tuynder M, Fiucci G, Prieur S, Lespagnol A, Géant A, Beaucourt S, Duflaut D, Besse S, Susini L, Cavarelli J, et al: Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci USA 101: 15364-15369, 2004.
28. Basta-Kaim A, Budziszewska B, Jagła G, Nowak W, Kubera M and Lasoń W: Inhibitory effect of antipsychotic drugs on the Con A-and LPS-induced proliferative activity of mouse splenocytes: A possible mechanism of action. J Physiol Pharmacol 57: 247-264, 2006.
29. Park MS, Dong SM, Kim BR, Seo SH, Kang S, Lee EJ, Lee SH and Rho SB: Thioridazine inhibits angiogenesis and tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian cancer xenografts. Oncotarget 5: 4929-4934, 2014.
30. Hercbergs A: Thioridazine: A radiation enhancer in advanced cervical cancer? Lancet 2: 737, 1988.
31. Gatto F and Hofland LJ: The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr Relat Cancer 18: R233-R251, 2011.
32. Akiyama S, Shiraishi N, Kuratomi Y, Nakagawa M and Kuwano M: Circumvention of multiple-drug resistance in human cancer cells by thioridazine, trifluoperazine, and chlorpromazine. J Natl Cancer Inst 76: 839-844, 1986.
33. Efferth T and Volm M: Reversal of doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms. Cancer Lett 70: 197-202, 1993.
34. Sutton LP and Rushlow WJ: The dopamine D2 receptor regulates Akt and GSK-3 via Dvl-3. Int J Neuropsychopharmacol 15: 965-979, 2012.
35. Castaing M, Loiseau A and Cornish-Bowden A: Synergy between verapamil and other multidrug-resistance modulators in model membranes. J Biosci 32: 737-746, 2007.